Cargando…
Comparison of azithromycin and erythromycin in the treatment of mycoplasma pneumonia in children
OBJECTIVE: To study and compare the clinical effects of azithromycin and erythromycin on children with mycoplasma pneumonia. METHODS: Total 132 children with mycoplasma pneumonia who were admitted to our hospital between November 2017 and September 2018 were selected as the research subjects. All th...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Professional Medical Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994860/ https://www.ncbi.nlm.nih.gov/pubmed/32063951 http://dx.doi.org/10.12669/pjms.36.2.1441 |
_version_ | 1783493270136946688 |
---|---|
author | Han, Rui Yu, Qianqian Zhang, Guohui Li, Baoqiang Han, Shuzhen Li, Guiying |
author_facet | Han, Rui Yu, Qianqian Zhang, Guohui Li, Baoqiang Han, Shuzhen Li, Guiying |
author_sort | Han, Rui |
collection | PubMed |
description | OBJECTIVE: To study and compare the clinical effects of azithromycin and erythromycin on children with mycoplasma pneumonia. METHODS: Total 132 children with mycoplasma pneumonia who were admitted to our hospital between November 2017 and September 2018 were selected as the research subjects. All the children were divided into an observation group and a control group according to random number table, 66 each. The observation group was treated with azithromycin, while the control group was treated with erythromycin. The therapeutic effect, incidence of adverse reactions and disappearance time of clinical symptoms were compared between the two groups. RESULTS: The total efficacy of the observation group was 98.04%, and that of the control group was 74.51%; there was a significant difference (X(2)=7.184, P=0.007). The incidence of adverse reactions in the observation group was 15.69%, significantly lower than that in the control group (41.18%) (X(2)=6.376, P=0.002). The disappearance of fever, cough, rale and X ray shadow of the observation group was significantly earlier than that of the control group, and the difference was statistically significant (P<0.05). CONCLUSION: Compared with erythromycin, azithromycin is more effective in the treatment of mycoplasma pneumonia in children. Azithromycin can further shorten the improvement time of clinical symptoms and signs and has few adverse reactions and high safety. It is worth clinical application. |
format | Online Article Text |
id | pubmed-6994860 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Professional Medical Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-69948602020-02-14 Comparison of azithromycin and erythromycin in the treatment of mycoplasma pneumonia in children Han, Rui Yu, Qianqian Zhang, Guohui Li, Baoqiang Han, Shuzhen Li, Guiying Pak J Med Sci Original Article OBJECTIVE: To study and compare the clinical effects of azithromycin and erythromycin on children with mycoplasma pneumonia. METHODS: Total 132 children with mycoplasma pneumonia who were admitted to our hospital between November 2017 and September 2018 were selected as the research subjects. All the children were divided into an observation group and a control group according to random number table, 66 each. The observation group was treated with azithromycin, while the control group was treated with erythromycin. The therapeutic effect, incidence of adverse reactions and disappearance time of clinical symptoms were compared between the two groups. RESULTS: The total efficacy of the observation group was 98.04%, and that of the control group was 74.51%; there was a significant difference (X(2)=7.184, P=0.007). The incidence of adverse reactions in the observation group was 15.69%, significantly lower than that in the control group (41.18%) (X(2)=6.376, P=0.002). The disappearance of fever, cough, rale and X ray shadow of the observation group was significantly earlier than that of the control group, and the difference was statistically significant (P<0.05). CONCLUSION: Compared with erythromycin, azithromycin is more effective in the treatment of mycoplasma pneumonia in children. Azithromycin can further shorten the improvement time of clinical symptoms and signs and has few adverse reactions and high safety. It is worth clinical application. Professional Medical Publications 2020 /pmc/articles/PMC6994860/ /pubmed/32063951 http://dx.doi.org/10.12669/pjms.36.2.1441 Text en Copyright: © Pakistan Journal of Medical Sciences http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Han, Rui Yu, Qianqian Zhang, Guohui Li, Baoqiang Han, Shuzhen Li, Guiying Comparison of azithromycin and erythromycin in the treatment of mycoplasma pneumonia in children |
title | Comparison of azithromycin and erythromycin in the treatment of mycoplasma pneumonia in children |
title_full | Comparison of azithromycin and erythromycin in the treatment of mycoplasma pneumonia in children |
title_fullStr | Comparison of azithromycin and erythromycin in the treatment of mycoplasma pneumonia in children |
title_full_unstemmed | Comparison of azithromycin and erythromycin in the treatment of mycoplasma pneumonia in children |
title_short | Comparison of azithromycin and erythromycin in the treatment of mycoplasma pneumonia in children |
title_sort | comparison of azithromycin and erythromycin in the treatment of mycoplasma pneumonia in children |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994860/ https://www.ncbi.nlm.nih.gov/pubmed/32063951 http://dx.doi.org/10.12669/pjms.36.2.1441 |
work_keys_str_mv | AT hanrui comparisonofazithromycinanderythromycininthetreatmentofmycoplasmapneumoniainchildren AT yuqianqian comparisonofazithromycinanderythromycininthetreatmentofmycoplasmapneumoniainchildren AT zhangguohui comparisonofazithromycinanderythromycininthetreatmentofmycoplasmapneumoniainchildren AT libaoqiang comparisonofazithromycinanderythromycininthetreatmentofmycoplasmapneumoniainchildren AT hanshuzhen comparisonofazithromycinanderythromycininthetreatmentofmycoplasmapneumoniainchildren AT liguiying comparisonofazithromycinanderythromycininthetreatmentofmycoplasmapneumoniainchildren |